Give Failed Bacterial Vaginosis Agents a Second Try

BY DIANA MAHONEY

New England Bureau

BOSTON — Women with bacterial vaginosis who fail initial treatment with either metronidazole or clindamycin may respond favorably to subsequent treatment with the same medication, results of a small study have shown.

Using data from 119 nonpregnant women with bacterial vaginosis who participated in a randomized controlled trial comparing topical metronidazole with topical clindamycin for the treatment of bacterial vaginosis, Dr. Katherine E. Bunge of the University of Pittsburgh Magee-Womens Research Institute and her colleagues conducted a nested cohort investigation to compare retreatment cure rates in women who failed initial treatment with either of these drugs. For the purposes of this study, bacterial vaginosis was defined clinically as the presence of at least three of the four Amsel's criteria.

Participants were randomized to receive metronidazole for 5 days or clindamycin for 3 days and were asked to return for follow-up visits at 7-12 days post treatment, 35-45 days post treatment, and 70-90 days post treatment. "At each [follow-up visit], the women were assessed for clinical cure of bacterial vaginosis, defined as less than two Amsel's criteria," Dr. Bunge said at the annual meeting of the Infectious Diseases Society for Obstetrics and Gynecology.

Study protocol dictated that women with early treatment failure, defined as clinical evidence of bacterial vaginosis at either the second or third follow-up visit, should be prescribed a second course of the medication to which they were initially randomized.

Of the initial 119 patients enrolled in the larger randomized controlled trial study, 104 had adequate clinical data for inclusion in the subgroup analysis. Of these women, 51 had evidence of failed initial treatment at follow-up visit two or three and 33 were retreated with the same medication they were initially randomized to receive, said Dr. Bunge. "These 33 women make up the cohort in this study," she said, noting that 19 of the women had been randomized initially to metronidazole treatment and 14 to clindamycin treatment. The mean age of the predominantly nonwhite cohort was 27 years.

Overall, 21 of the 33 women with a single early clinical failure responded

Early treatment failure of bacterial vaginosis is common, and there are a lack of data that remotely touch on the best management course.

successfully to retreatment. "giving a cure rate of 64%," Dr. Bunge reported. Retreatment resulted in 11 cures in the metronidazole arm and 10 in the clindamycin arm. There was no statistical signif-

icance in the difference between the respective cure rates of 58% and 71%, she said.

While the study was not powered to detect differences between women in whom retreatment was and was not successful. said Dr. Bunge, "there were no obvious differences between the two groups in terms of therapy, smoking, age, race, or bacterial vaginosis history.'

Of the 12 women who experienced a second treatment failure, only 2 received a third course of the same medication to which they were initially randomized and neither had clinical evidence of cure at the subsequent follow-up. The remaining 10 women with two treatment failures were retreated with a different medication, "but only 2 experienced cure at follow-up," said Dr. Bunge. "This suggests that women who experience repetitive early treatment failures are unlikely to respond favorably to retreatment."

The study is limited by its small size, Dr. Bunge noted. "Unfortunately, only 65% of the early treatment failures were retreated with the same medication, as had been our intention." In addition, she said, "longterm follow-up data were not available.

Despite the limitations, the findings do lead to the conclusion that for women who experience a single early treatment failure, "retreatment with the same medication is a reasonable approach," said Dr. Bunge. This is important, she added, "because early treatment failure of bacterial vaginosis is a common problem, and there is [a scarcity of] data that remotely touch on the best management course."

REGISTER NOW!

Family Practice News® & Internal Medicine News®



Boston University School of Medicine

JOINTLY SPONSOR

Endocrinology in the News

A Continuing Medical Education Conference designed for all health care professionals involved in the management of metabolic disorders and other issues related to endocrinology.

April 12 – 13, 2008 Loews Philadelphia Hotel, Philadelphia

Topic Highlights

Preventing Type 2 Diabetes and Cardiovascular Disease: Lessons From Recent Trials

Incretins - What's Here and What's Coming?

Metabolic Syndrome - Why the Controversy?

Should We Care About HDL Cholesterol?

Nutritional Approach to Obesity: High vs. Low Carb Diet?

Conditions and Comorbidities Affecting Thyroid Function Tests

When to Suspect Adrenal Hypertension

Testosterone Replacement and the Aging Baby Boomer

The Differential Diagnosis of Thin Bones

Bisphosphanates and Recombinant PTH: Indications, Benefits and Complications

Vitamin D Therapy - Expanding Clinical Applications

PCOS and Fertility

Estrogen Therapy and the Menopausal Woman

Case Presentations... and more

Tuition

Physicians:

Early Bird: \$450 Early Bird: \$300 After Dec. 1st: \$495 After Dec. 1st: \$325

Accommodations

Loews Philadelphia Hotel (215) 627-1200

Mention the Family Practice News, Internal Medicine News and Boston University School of Medicine group to receive the special rate of \$199 per night.

Educational Needs Addressed: This conference will provide participants with a corpresenting up-to-date information in the diagnosis and management of these disorders illnesses and androgen-related problems such as polycystic ovary syndrome (PCOS).

- Educational Objectives: At the conclusion of this conference, participants will be able to:

 Articulate recent advances in the management of metabolic disorders and other endocrinology-related is
- Identify signs and symptoms that suggest metabolic disorders.
- Explain the management and treatment strategies for metabolic disorders, including, but not limited to, diabetes control and complications of thyroid disorders, hypertension, and osteoporosis.

Accreditation: This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Boston University School of Medicine and Elsevier/IMNG. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

ton University School of Medicine designates this educational activity for a maximum of **9.5 AMA PRA Category 1 Credit(s)™**. Physicians should claim credit commensurate with the extent of their participation in the activity

Check our websites for conference updates.

www.bu.edu/cme • www.familypracticenews.com • www.internalmedicinenews.com

Course Director

Elliot Sternthal, MD Clinical Director of Diabetes Services Boston Medical Center Assistant Professor of Medicine Boston University School of Medicine

Faculty

Shalender Bhasin, MD

Boston Medical Center Boston University School of Medicine

Susan S. Braithwaite, MD

Seth Braunstein, MD, PhD

Andrea Coviello, MD, MSE

Diana Cullum-Dugan, RD, LD

Alan Farwell, MD

Osama Hamdy, MD, PhD

Stephanie Lee, MD, PhD

Alan Malabanan, MD
Beth Israel Deaconess Medical Center

Norman A. Mazer, MD. PhD

Marie E. McDonnell, MD

George J. Philippides, MD, FACC

Boston University School of Medicine Ernst J. Schaefer. MD

Vin Tangpricha, MD, PhD

ersity School of Medicine

Andrea L. Utz, MD, PhD Harvard University

To register, please contact:

Boston University School of Medicine

Continuing Medical Education

715 Albany Street, A305 Boston, MA, 02118

Phone: (617) 638-4605 Toll-free: (800) 688-2475

Fax: (617) 638-4905

E-mail: cme@bu.edu

Website: http://www.bu.edu/cme